GDP方案治疗非霍奇金淋巴瘤的疗效及预后的影响因素  

Efficacy of GDP Regimen in the Treatment of non-Hodgkin's Lymphoma and Influencing Factors of Prognosis

作　　者：王美佳 钟旭书 曾依伶 廖已函 WANG Meijia;ZHONG Xushu;ZENG Yiling(Shangjin Nanfu Hospital,Chengdu,611731)

机构地区：[1]成都上锦南府医院,611731 [2]四川大学华西医院,610041

出　　处：《实用癌症杂志》2020年第9期1562-1565,共4页The Practical Journal of Cancer

摘　　要：目的观察GDP方案(吉西他滨+顺铂+地塞米松)治疗非霍奇金淋巴瘤(NHL)的疗效,分析影响患者预后的相关因素。方法研究对象为80例行GDP治疗的NHL患者。观察近期疗效,统计患者临床特点、治疗情况、生存情况,分析其预后影响因素。结果80例NHL患者行GDP化疗2个周期后ORR为65.00%,主要不良反应为骨髓抑制,其中血小板减少、中性粒细胞减少Ⅲ~Ⅳ度发生率分别为21.25%、15.00%。患者中位生存时间为27.10个月,1、2、3年总生存率分别为82.50%、53.75%、36.25%。行GDP化疗NHL患者的3年总生存率与临床分期、IPI、结外病变数、B症状、血清LDH水平、血清β2-MG水平、近期疗效等因素有关(P<0.05)。临床分期Ⅲ~Ⅳ期、IPI>2分、有B症状、近期疗效为(SD+PD)是影响行GDP化疗NHL患者预后的独立危险因素(P<0.05)。结论GDP方案治疗NHL的疗效及患者耐受性良好,临床分期Ⅲ~Ⅳ期、IPI>2分、有B症状、近期疗效为(SD+PD)者预后较差,应予以重视。Objective To observe the efficacy of GDP regimen(gemcitabine+cisplatin+dexamethasone)in the treatment of non-Hodgkin's lymphoma(NHL),and to analyze the related factors affecting the prognosis of patients.Methods The subjects were 80 NHL patients who underwent GDP treatment.The short-term efficacy was observed,and the clinical characteristics,treatment and survival of patients were statistically analyzed,and the influencing factors for prognosis were analyzed.Results ORR was 65.00%among 80 NHL patients after 2 cycles of GDP chemotherapy.The main adverse reaction was myelosuppression,and the incidence rates of III^IV degree of thrombocytopenia and neutropenia were 21.25%and 15.00%respectively.The median survival time of patients was 27.10 months,and the 1-,2-and 3-year overall survival rates were 82.50%,53.75%and 36.25%,respectively.The 3-year overall survival rate of NHL patients underwent GDP was related to the factors of clinical stage,IPI,number of extranodal lesions,B symptoms,serum LDH level,serum β2-MG level and short-term efficacy(P<0.05).Clinical stage III^IV,IPI>2 point,B symptoms and short-term efficacy(SD+PD)were independent risk factors for the prognosis of NHL patients undergoing GDP(P<0.05).Conclusion GDP regimen has good efficacy and good tolerance in the treatment of NHL.Patients with clinical stage III^IV,IPI>2 points,B symptoms and short-term efficacy(SD+PD)have a poor prognosis and should be taken seriously.

关 键 词：非霍奇金淋巴瘤 GDP方案 预后 影响因素 

分 类 号：R733.4[医药卫生—肿瘤]